Jean Boulle Group Announces Successful First Human Implants of the Nickel-Titanium Tendyne Transcatheter Mitral Valve

PR58920

LUXEMBOURG, Dec. 10, 2014/PRN=KYODO JBN/--

    Boulle Medtech Ltd., a Jean Boulle Group private company focusing on

medical technology, and founding investor of Tendyne Holdings, Inc.

("Tendyne"), is pleased to announce that Tendyne's Transcatheter Mitral Valve

device has been successfully implanted in three patients. The procedures are

the first in a series to be performed at various hospitals worldwide. Tendyne

reports that the patients had severe mitral regurgitation that was eliminated

after the procedure was performed via a trans-apical approach without

cardio-pulmonary bypass (known as a trans-catheter mitral valve implantation,

or "TMVI"). These first three procedures were conducted at the Royal Brompton

Hospital in London, England by Dr. Neil Moat, a leading expert in mitral valve

and trans-catheter mitral valve implantation. Tendyne further reports that all

three patients had no major in-hospital complications and have been discharged

from hospital.

    The Tendyne TMVI is a fully-retrievable and repositionable, apically

tethered tri-leaflet porcine pericardial valve sewn onto a nickel-titanium

frame specifically designed to address the complex mitral anatomy of

functional, degenerative and mixed etiology mitral regurgitation. Left

untreated, mitral regurgitation can lead to heart failure and death. Implanted

in a beating heart in a hybrid operating room, the Tendyne valve has

proprietary and patented features that permit a significantly less invasive

procedure to mitral valve treatment than open heart surgery.

    For more information contact

    Audrey Richardson at +352-222-512,

    audrey@jeanboullegroup.com,

    or go to our website http://www.jeanboullegroup.com

    SOURCE: Jean Boulle Group